sunitinib drug pathway sunitinib pharmacodynamics pathway 2012-10-04T15:58:42Z PW:0001114 The pathway of sunitinib-target interaction and of the biochemical or physiological responses to drug. Sunitinib is a multikinase inhibitor approved for the treatment of renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug. pathway vpetri